Prodia | $15,000,000 | (Jul 3, 2024)
BoldHue, Inc. | $3,400,000 | (Jul 3, 2024)
Redactive | $7,500,000 | (Jul 3, 2024)
Hemab Therapeutics
Denmark
- Copenhagen, Capital Region
- 22/02/2023
- Series B
- $135,000,000
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
- Industry Biotechnology Research
- Website https://hemab.com/
- LinkedIn https://www.linkedin.com/company/hemabaps/
Related People
Benny SorensenFounder
United States -
Cambridge, Massachusetts
Experienced patient centric Biotechnology Executive with demonstrated translational research, early- intermediate- and late stage clinical development experience. Strong entrepreneurial profile and successful track record of building lean high-performing R&D organizations. Excellent presentation and discussion skills. Extensive pharma-, biotech- and clinical academic high profile network.
Vida Global | $3,000,000 | (Jul 3, 2024)
Steep | $4,303,680 | (Jul 3, 2024)
Cluby | $3,117,935 | (Jul 3, 2024)
Watchyourhealth.com | $5,000,000 | (Jul 3, 2024)
Tembo(US) | $14,000,000 | (Jul 3, 2024)
Wify Technologies | $2,993,443 | (Jul 2, 2024)
Blueroomcare Business | Undisclosed Amount | (Jul 2, 2024)
Comet(INDIA) | $5,000,000 | (Jul 2, 2024)
Cautio | $778,300 | (Jul 2, 2024)